AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An anti-tumor agent comprising ~~one or more~~ a tubulin polymerization-inhibitory active substance having anti-tumor activity and one or more anti-inflammatory active substance, wherein said tubulin polymerization-inhibitory active substance having anti-tumor activity is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.

2. (Canceled)

3. (Original) The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is an anti-inflammatory active steroid substance.

4. (Original) The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, cortisol, and derivatives thereof.

5. (Original) The anti-tumor agent according to Claim 4, wherein the Dexamethasone and derivatives thereof are selected from the group consisting of Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.

6. (Original) The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is selected from the group consisting of anti-inflammatory active steroid substances and analogous compounds thereof, anti-inflammatory active non-

steroid substances and analogous compounds thereof, and anti-inflammatory or immuno-suppressive active substances.

7. (Original) The anti-tumor agent according to Claim 6, wherein the anti-inflammatory active substance is an anti-inflammatory active steroid substance.

8. (Original) The anti-tumor agent according to Claim 6, wherein the anti-inflammatory active substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, cortisol, and derivatives thereof.

9. (Original) The anti-tumor agent according to Claim 8, wherein the Dexamethasone and derivatives thereof are selected from the group consisting of Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.

10. (Currently Amended) The anti-tumor agent according to Claim 1, wherein ~~the tubulin polymerization-inhibitory active substance is selected from the group consisting of combretastines and derivatives thereof and stilbenes and derivatives thereof, and~~ the anti-inflammatory active substance is selected from the group consisting of Dexamethasone and derivatives thereof.

11. (Currently Amended) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride ~~or salt thereof~~.

12. (Original) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical preparation and the anti-inflammatory active substance is in the form of an anti-inflammatory agent.

13. (Original) The anti-tumor agent according to Claim 12, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

14. (Original) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a quantity ranging from 0.1-10000mg.

15. (Original) The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg

16. (Withdrawn; Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising an effective amount of ~~one or more~~ a tubulin polymerization-inhibitory active substance having anti-tumor activity and an effective amount of one or more an anti-inflammatory active substance, wherein said tubulin polymerization-inhibitory active substance having anti-tumor activity is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.

17. (Withdrawn) The method according to Claim 16, wherein said subject in need thereof is a human.

18. (Withdrawn) The method according to Claim 16, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

19. (Withdrawn) The method according to Claim 16, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

20. (Canceled)

21. (Withdrawn) The method according to Claim 16, wherein the anti-inflammatory active substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, cortisol, and derivatives thereof.

22. (Withdrawn; Currently Amended) A method for treatment of tumors, comprising administering to a subject in need thereof (a) a composition comprising and effective amount of ~~one or more~~ a tubulin polymerization-inhibitory active substance having anti-tumor activity and (b) a composition comprising an effective amount of one or more anti-inflammatory active substance, wherein said tubulin polymerization-inhibitory active substance having anti-tumor activity is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.

23. (Withdrawn) The method according to Claim 22, wherein (a) and (b) are administered simultaneously or sequentially.

24. (Withdrawn) The method according to Claim 22, wherein said subject in need thereof is a human.

25. (Withdrawn) The method according to Claim 22, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

26. (Withdrawn) The method according to Claim 22, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

27. (Canceled)

28. (Withdrawn) The method according to Claim 22, wherein the anti-inflammatory active substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, cortisol, and derivatives thereof.

29. (Original) A composition comprising (a) (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide, an ester thereof, or an salt thereof, and (b) dexamethasone, an ester thereof, or an salt thereof.

30. (New) An anti-tumor agent comprising one or more tubulin polymerization-inhibitory active substance having anti-tumor activity and an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.

31. (New) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is selected from the group consisting of combretastatines and derivatives thereof, vinca alkaloids and derivatives thereof, colchicinoids and derivatives thereof, dolastatins and derivatives thereof, podophyllotoxins and derivatives thereof, steganacins and derivatives thereof, amphethiniles and derivatives thereof, fiavonoids and derivatives thereof, rhizoxins and derivatives thereof, curacins A and derivatives thereof, epothilones A and derivatives thereof, epothilones B and derivatives thereof, welwistatins and derivatives thereof, phenstatins and derivatives thereof, 2-strylquinazoline-4(3H)-ones and derivatives thereof, stilbenes and derivatives thereof, 2-aryl-l,8-naphthyridin-4(1H)-ones and derivatives thereof, 5,6-dihydroindolo(2,1-a) isoquinolines and derivatives thereof, 2,3-benzo(b)thiophenes and derivatives thereof, 2,3-substituted benzo(b)furans and derivatives thereof, 2,3-substituted indoles and derivatives thereof, and 2-methoxyestradiol.

32. (New) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is selected from the group consisting of combretastines and derivatives thereof and stilbenes and derivatives thereof, and the anti-inflammatory active substance is selected from the group consisting of Dexamethasone and derivatives thereof.

33. (New) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or salt thereof.

34. (New) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride.

35. (New) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical preparation and the anti-inflammatory active substance is in the form of an anti-inflammatory agent.

36. (New) The anti-tumor agent according to Claim 35, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

37. (New) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a quantity ranging from 0.1-10000mg.

38. (New) The anti-tumor agent according to Claim 30, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg

39. (New) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising an effective amount of one or more tubulin polymerization-inhibitory active substance having anti-tumor activity and an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.

40. (New) The method according to Claim 39, wherein said subject in need thereof is a human.

41. (New) The method according to Claim 39, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

42. (New) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

43. (New) The method according to Claim 39, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is selected from the group consisting of combretastatines and derivatives thereof, vinca alkaloids and derivatives thereof, colchicinoids and derivatives thereof, dolastatins and derivatives thereof, podophyllotoxins and derivatives thereof, steganacins and derivatives thereof, amphethiniles and derivatives thereof, fiavonoids and derivatives thereof, rhizoxins and derivatives thereof, curacins A and derivatives thereof, epothilones A and derivatives thereof, epothilones B and derivatives thereof, welwistatins and derivatives thereof, phenstatins and derivatives thereof, 2-

strylquinazoline-4(3H)-ones and derivatives thereof, stilbenes and derivatives thereof, 2-aryl-l,8-naphthyridin-4(1H)-ones and derivatives thereof, 5,6-dihydroindolo(2,1-a) isoquinolines and derivatives thereof, 2,3-benzo(b)thiophenes and derivatives thereof, 2,3-substituted benzo(b)furans and derivatives thereof, 2,3-substituted indoles and derivatives thereof, and 2-methoxyestradiol.

44. (New) A method for treatment of tumors, comprising administering to a subject in need thereof (a) a composition comprising and effective amount of one or more tubulin polymerization-inhibitory active substance having anti-tumor activity and (b) a composition comprising an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.

45. (New) The method according to Claim 44, wherein (a) and (b) are administered simultaneously or sequentially.

46. (New) The method according to Claim 44, wherein said subject in need thereof is a human.

47. (New) The method according to Claim 44, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

48. (New) The method according to Claim 44, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

49. (New) The method according to Claim 44, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is selected from the group consisting of combretastatines and derivatives thereof, vinca alkaloids and derivatives thereof, colchicinoids and derivatives thereof, dolastatins and derivatives thereof, podophyllotoxins and derivatives thereof, steganacins and derivatives thereof, amphethiniles and derivatives thereof, fiavonoids and derivatives thereof, rhizoxins and derivatives thereof, curacins A and derivatives thereof, epothilones A and derivatives thereof, epothilones B and derivatives thereof, welwistatins and derivatives thereof, phenstatins and derivatives thereof, 2-strylquinazoline-4(3H)-ones and derivatives thereof, stilbenes and derivatives thereof, 2-aryl-l,8-naphthyridin-4(1H)-ones and derivatives thereof, 5,6-dihydroindolo(2,1-a) isoquinolines and derivatives thereof, 2,3-benzo(b)thiophenes and derivatives thereof, 2,3-substituted benzo(b)furans and derivatives thereof, 2,3-substituted indoles and derivatives thereof, and 2-methoxyestradiol.

SUPPORT FOR THE AMENDMENTS

Claims 2, 20, and 27 have been canceled.

Claims 1, 10, 11, 16, and 22 have been amended.

Claims 30-49 have been added.

The amendment to Claims 1, 10, 11, 16, and 22 and new Claims 30-49 are supported by Claims 1-29 as originally filed. Further support for the amendment to Claims 1, 10, 11, 16, and 22 and new Claims 30-49 is provided by the specification as originally filed, for example at page 6, lines 12-14 and the Examples.

No new matter has been added by the present amendment.

Applicants wish to note that new Claims 30-38 correspond to previously elected subject matter. Specifically, Claim 30 corresponds to a combination of original Claims 1, 4, and 5. Therefore, Claims 30-38 should be entered and examined in the present application. New Claims 39-49 correspond to original Claims 16-28 in which the anti-inflammatory active substance has been limited in the same manner as in Claim 30. Claims 39-49 are method claims, which were withdrawn by non-election. Nonetheless, with the finding of allowability of the composition claims, Claims 16-28 and 39-49 should be rejoined and examined (MPEP §821.04).